| 1 |
31749252 | Bivalirudin during thrombolysis with catheter-directed tPA in a heparin-refractory patient: A case report. | 2020 Feb |
1 |
| 2 |
20445443 | Mechanism of the synergistic effect between oversulfated chondroitin-6-sulfate and lysine or 6-aminohexanoic acid in enhancing the in-vitro activation of glutamic plasminogen by tissue plasminogen activator or urokinase. | 2010 Jul |
2 |
| 3 |
18301879 | Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery. | 2008 Jul |
1 |
| 4 |
18638092 | Tissue plasminogen activator as a hemodialysis catheter locking solution. | 2008 Jul |
1 |
| 5 |
18685430 | Effect of oversulfation on the chemical and biological properties of chondroitin-4-sulfate. | 2008 Sep |
1 |
| 6 |
18976135 | The ATTEMPTS delivery systems for macromolecular drugs. | 2008 Nov |
2 |
| 7 |
16260060 | Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis. | 2005 Dec 10 |
3 |
| 8 |
14964479 | Intravenous thrombolysis for acute stroke. | 2004 Jan |
1 |
| 9 |
15726889 | Mechanism of the stimulatory effect of native fucoidan, highly sulfated fucoidan and heparin on plasminogen activation by tissue plasminogen activator: the role of chloride. | 2004 Oct-Dec |
1 |
| 10 |
12679132 | Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model. | 2003 Jan 1 |
1 |
| 11 |
11991242 | Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium. | 2002 Jan |
1 |
| 12 |
12441912 | Thrombolytic fibrin specificity influences activated partial thromboplastin time prolongation in vitro. | 2002 Dec |
1 |
| 13 |
11389993 | ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs. | 2001 May 14 |
1 |
| 14 |
12577350 | [Clinical observation on effect of intervention therapy with anticoagulant in treating patients of hypertension complicated with acute ischemic cerebrovascular disease]. | 2001 Apr |
1 |
| 15 |
10756332 | A novel heparin/protamine-based pro-drug type delivery system for protease drugs. | 2000 May |
9 |
| 16 |
10340997 | Functionally inactive protein C inhibitor in seminal plasma may be associated with infertility. | 1999 Jun |
1 |
| 17 |
9453518 | Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. | 1998 Jan |
1 |
| 18 |
9626825 | Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. | 1998 Jun |
2 |
| 19 |
9664197 | Reperfusion therapy for acute myocardial infarction. Which strategy for which patient? | 1998 Jul |
1 |
| 20 |
10608050 | A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study. | 1998 |
1 |
| 21 |
9140688 | Is heparin of value in the management of acute myocardial infarction? | 1997 Apr |
1 |
| 22 |
9241751 | Effects of heparin therapy on fibrinolysis in patients with pulmonary embolism. | 1997 Jun |
1 |
| 23 |
9307014 | Heparin inhibits the binding of basic fibroblast growth factor to cultured human aortic smooth-muscle cells. | 1997 Sep 15 |
1 |
| 24 |
8623729 | A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. | 1996 Apr 15 |
1 |
| 25 |
8739535 | Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions. | 1996 Mar |
1 |
| 26 |
8874867 | Interaction of reteplase with heparin. A comparison between reteplase and alteplase. | 1996 Jul |
8 |
| 27 |
8909909 | ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction. | 1996 Oct |
1 |
| 28 |
8925311 | [Adjuvant therapy in patients with acute myocardial infarct]. | 1996 Jul |
1 |
| 29 |
8963700 | [Antithrombotic therapy in acute myocardial infarct]. | 1996 Aug |
1 |
| 30 |
10602554 | Enhancing Thrombolysis with Adjunctive Therapy. | 1996 |
1 |
| 31 |
7481155 | [Myocardial infarction and revascularization. Current indications]. | 1995 |
1 |
| 32 |
7588083 | Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. | 1995 Jul |
1 |
| 33 |
7731256 | Adjunctive therapy in the management of patients with acute myocardial infarction. | 1995 May |
1 |
| 34 |
10172669 | Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction. | 1995 Nov |
1 |
| 35 |
7807964 | Heparin selectively inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells. | 1994 Dec |
3 |
| 36 |
7863705 | [Different therapeutic regimens in thrombolysis of acute myocardial infarct]. | 1994 |
1 |
| 37 |
7921367 | The role of thrombolytic therapy for acute myocardial infarction. | 1994 May |
1 |
| 38 |
7952425 | Lack of degradation of antithrombin III by tissue-type plasminogen activator or plasmin. | 1994 Jul |
2 |
| 39 |
8016815 | Effects of heparan sulfate analogue or other sulfated polysaccharides on the activation of plasminogen by t-PA or u-PA. | 1994 Mar 1 |
1 |
| 40 |
8034236 | Effect of low-dose heparin treatment on fibrinolysis in patients with previous myocardial infarction. | 1993 Nov-Dec |
4 |
| 41 |
8128448 | Interaction of plasminogen activators and plasminogen with heparin: effect of ionic strength. | 1993 Nov 15 |
3 |
| 42 |
8261475 | The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration. | 1993 |
1 |
| 43 |
8292721 | Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis. | 1993 Oct |
4 |
| 44 |
1280862 | Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise. | 1992 Nov 10 |
1 |
| 45 |
1520875 | Heparin enhances active site-dependent binding of tissue-type plasminogen activator to endothelial cells. | 1992 Sep 15 |
1 |
| 46 |
1643205 | Fibrin clots obtained from plasma containing heparin show a higher sensitivity to t-PA-induced lysis. | 1992 Jun |
4 |
| 47 |
1728444 | Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo. | 1992 Jan |
1 |
| 48 |
1661447 | Standard heparin but not LMW heparin induces a concomitant increase of t-PA and PAI-1 without modification of global fibrinolysis: study after 60 days treatment. | 1991 Sep 1 |
1 |
| 49 |
1708387 | The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a). | 1991 Apr 25 |
3 |
| 50 |
1850874 | The initial release of t-PA induced by dDAVP is more important with low molecular weight heparin than with unfractionated heparin. | 1991 Jan 23 |
2 |